ZYDUS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ZYDUS LIFESCIENCES have increased by 14.08% YoY .
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has decreased by -55.80 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ZYDUS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 532321|NSE : ZYDUSLIFE]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹17,237 Cr | ₹15,110 Cr | ₹14,404 Cr | ₹14,253 Cr | ₹13,166 Cr |
| Expenses | ₹13,666 Cr | ₹11,935 Cr | ₹11,018 Cr | ₹11,473 Cr | ₹10,187 Cr |
| Operating Profit (Excl OI) | ₹3,572 Cr | ₹3,175 Cr | ₹3,385 Cr | ₹2,780 Cr | ₹2,978 Cr |
| Other Income | ₹475 Cr | ₹391 Cr | ₹75 Cr | ₹117 Cr | ₹209 Cr |
| Interest | ₹130 Cr | ₹127 Cr | ₹186 Cr | ₹342 Cr | ₹196 Cr |
| Depreciation | ₹723 Cr | ₹713 Cr | ₹670 Cr | ₹697 Cr | ₹599 Cr |
| Profit Before Tax | ₹2,590 Cr | ₹2,838 Cr | ₹2,399 Cr | ₹1,495 Cr | ₹2,382 Cr |
| Profit After Tax | ₹2,002 Cr | ₹2,326 Cr | ₹2,206 Cr | ₹1,176 Cr | ₹1,852 Cr |
| Consolidated Net Profit | ₹1,960 Cr | ₹4,487 Cr | ₹2,134 Cr | ₹1,177 Cr | ₹1,849 Cr |
| Earnings Per Share (Rs) | ₹19.37 | ₹43.82 | ₹20.84 | ₹11.49 | ₹18.05 |
| PAT Margin (%) | 5.90 | 7.87 | 7.64 | 8.25 | 14.07 |
| ROE(%) | 11.60 | 15.51 | 18.88 | 11.32 | 19.36 |
| ROCE(%) | 13.64 | 15.30 | 14.38 | 10.02 | 15.89 |
| Total Debt/Equity(x) | 0.07 | 0.25 | 0.35 | 0.77 | 0.76 |
Key Financials |
||
| Market Cap | : | ₹ 111,129.8 Cr |
| Revenue (TTM) | : | ₹ 19,547.4 Cr |
| Net Profit(TTM) | : | ₹ 3,831.4 Cr |
| EPS (TTM) | : | ₹ 38.1 |
| P/E (TTM) | : | 29.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
| CIPLA | 3.5% | 4.2% | 51.8% |
| DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
| DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
| MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
| TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
| LUPIN | 1.5% | 4.2% | 109.2% |
| AUROBINDO PHARMA | 3.1% | 7.9% | 81.3% |
ZYDUS LIFESCIENCES Revenues
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 14.08 % |
| 5 Yr CAGR | 6.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹17,237 Cr | 14.08 | |
| Mar2022 | ₹15,110 Cr | 4.90 | |
| Mar2021 | ₹14,404 Cr | 1.06 | |
| Mar2020 | ₹14,253 Cr | 8.26 | |
| Mar2019 | ₹13,166 Cr | - | |
ZYDUS LIFESCIENCES Operating Profit
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | 12.51 % |
| 5 Yr CAGR | 4.65 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,572 Cr | 12.51 | |
| Mar2022 | ₹3,175 Cr | -6.22 | |
| Mar2021 | ₹3,385 Cr | 21.76 | |
| Mar2020 | ₹2,780 Cr | -6.65 | |
| Mar2019 | ₹2,978 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.38 % |
| 5 Yr CAGR | -2.17 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 20.72% | -1.38 | |
| Mar2022 | 21.01% | -10.60 | |
| Mar2021 | 23.5% | 20.45 | |
| Mar2020 | 19.51% | -13.75 | |
| Mar2019 | 22.62% | - | |
ZYDUS LIFESCIENCES Profit After Tax
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | -56.31 % |
| 5 Yr CAGR | 1.47 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,960 Cr | -56.31 | |
| Mar2022 | ₹4,487 Cr | 110.32 | |
| Mar2021 | ₹2,134 Cr | 81.34 | |
| Mar2020 | ₹1,177 Cr | -36.36 | |
| Mar2019 | ₹1,849 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -25.03 % |
| 5 Yr CAGR | -19.53 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 5.9 % | -25.03 | |
| Mar2022 | 7.87 % | 3.01 | |
| Mar2021 | 7.64 % | -7.39 | |
| Mar2020 | 8.25 % | -41.36 | |
| Mar2019 | 14.07 % | - | |
ZYDUS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | -55.80 % |
| 5 Yr CAGR | 1.78 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹19 | -55.80 | |
| Mar2022 | ₹44 | 110.27 | |
| Mar2021 | ₹21 | 81.38 | |
| Mar2020 | ₹11 | -36.34 | |
| Mar2019 | ₹18 | - | |
ZYDUS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 532321|NSE : ZYDUSLIFE]
| Y-o-Y | -10.85 % |
| 5 Yr CAGR | -3.75 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 13.64% | -10.85 | |
| Mar2022 | 15.3% | 6.40 | |
| Mar2021 | 14.38% | 43.51 | |
| Mar2020 | 10.02% | -36.94 | |
| Mar2019 | 15.89% | - | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,104.5 |
| Current MarketCap | : | ₹ 111,129.8 Cr |
| Updated EOD on | : | May 18,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | 12.2% |
18% |
103.8% |
| SENSEX | 1.7% |
1.5% |
18.7% |
ZYDUS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MOMENTUM | 5.6% | 8.1% | 79.7% |
| S&P BSE 400 MIDSMALLCAP | 5.1% | 6% | 57.9% |
| S&P BSE 150 MIDCAP | 4.8% | 6.7% | 57.6% |
| S&P BSE QUALITY | 4.4% | 7.2% | 49.4% |
| S&P BSE DIVIDEND STABILITY | 3.4% | 3.9% | 55% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY NEXT 50 | 5.1% | 9% | 65% |
| NIFTY200 MOMENTUM 30 INDEX | 5.1% | 9.3% | 71.6% |
| NIFTY 100 ALPHA 30 | 4.6% | 6.6% | 69.3% |
| NIFTY500 MULTICAP 50:25:25 | 3.8% | 4.2% | 44.5% |
| NIFTY ALPHA QTY VAL LOW-VOL 30 | 3.5% | 6.5% | 61.7% |
You may also like the below Video Courses
FAQ about ZYDUS LIFESCIENCES Financials
How the annual revenues of ZYDUS LIFESCIENCES have changed ?
The Revenues of ZYDUS LIFESCIENCES have increased by 14.08% YoY .
How the Earnings per Share (EPS) of ZYDUS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ZYDUS LIFESCIENCES has decreased by -55.80 % YoY .
Check out Intrinsic Value of Peers of ZYDUS LIFESCIENCES
Compare Stock Analytics of Peers of ZYDUS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
